mastodontech.de ist einer von vielen unabhängigen Mastodon-Servern, mit dem du dich im Fediverse beteiligen kannst.
Offen für alle (über 16) und bereitgestellt von Markus'Blog

Serverstatistik:

1,4 Tsd.
aktive Profile

#biotech

21 Beiträge18 Beteiligte1 Beitrag heute

"“China [could] lead the next generation of AI-enabled drug discovery,” Zhang told Rest of World, citing the integration of software and hardware innovations across the entire R&D pipeline — from drug targeting to candidate screening and data validation. She estimated AI could unlock $15 billion to $28 billion in annual value for drug discovery globally."

restofworld.org/2025/ai-drug-d

#ai
#drugs
#china
#biotech

A stylized robot with a white head and a single yellow eye, pointing and surrounded by various colorful pills and capsules on a vibrant pink background.
Rest of World · China’s AI drug discovery companies land huge deals with Big PharmaMultibillion-dollar partnerships show China’s rising influence in AI-driven pharmaceuticals. 

GLP-1-der: Weight, there’s more.

Scrutinizing the poor beast, the scientists had a “eureka moment” when they discovered that anglerfish genes coded for several peptides related to the gut hormone glucagon. Scientists later identified that hormone as “glucagon-like peptide 1”—GLP-1. Further research showed that GLP-1 reduced blood sugar levels in mammals, making it a promising candidate for diabetes medication. The problem, however, was that the molecule’s half-life was much too short to serve as a useful medicine.

When he studied the lizard’s venom, he discovered that its saliva contained a hormone called exendin-4, which worked much the same way as GLP-1, but lasted much longer.

If GLP-1 Drugs Are Good For Everything, Should We All Be on Them?

Derek Thompson’s GLP-1 essay is a highly recommended read. He explores the genesis, explanations on why it works and posits if all of humanity will benefit from being on it.

Derek Thompson · If GLP-1 Drugs Are Good For Everything, Should We All Be on Them?Von Derek Thompson
#biotech#glp1#medicine

ARTBIO expands board with four industry experts, signaling strategic growth in radiopharmaceutical cancer therapies. Co-founder Roy Larsen transitions to technical advisory role. Exciting developments ahead for innovative cancer treatment. #Biotech #Cancer